Treadwell TX Announces FDA Fast Track Designation Granted to CFI-400945 for the Treatment of Acute Myeloid Leukemia #treadwelltx #AML #pathtobetter #fda #lymphoma prnewswire.com/news-releases/…

#Treadwelltx Announces Initiation of Patient Dosing in TWT-203, a Phase 1b/2 study of TTK Inhibitor CFI-402257, in Patients with ER+/Her2- Breast cancer prnewswire.com/news-releases/…

Treadwell welcomes Carmen Merritt, our new Vice President, Human Resources #treadwell #pathtobetter #talent #culture #biotech

Thank you Jenny Kim for your contributions at Treadwell, Jeannine Madere appreciated your efforts! The University of Queensland Master of Pharmaceutical Industry Practice delivers excellent talent! #pathtobetter #cancer #immunology #treadwell UQ News

Treadwell Therapeutics is pleased to announce a presentation for CFI-402411, an oral, first-in-class inhibitor HPK1, at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting from Nov. 8-12, 2022 in Boston, MA. #SITC22 #SITC2022 prnewswire.com/news-releases/…

Treadwell Therapeutics is pleased to announce four abstracts highlighting CFI-402257 and CFI-400945, our potent and selective inhibitors of TTK and PLK4, respectively, have been accepted for presentation at the 2022 SABCS from December 6-10, 2022. prnewswire.com/news-releases/…

Treadwell Therapeutics, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer. prnewswire.com/news-releases/…

We are very excited to announce the formation of our SAB to support Treadwell's efforts to treat patients with unmet needs. businesswire.com/news/home/2024…

We are very pleased to announce the FDA granted orphan drug status for ocifisertib (CFI-400945) and the appointment of Brenda Marczi, as SVP and Head of Regulatory Affairs can01.safelinks.protection.outlook.com/?url=https%3A%…

Congratulations to co-founder, Dr. Tak Mak for being elected as a Fellow of American Association for the Advancement of Science (AAAS) and for his lifelong and distinguished contributions to immunology and cancer research. #AAAS #Treadwelltx aaas.org/news/aaas-welc…

Congratulations to our senior scientist Dr. Tak Mak, who ranked as #8  and #9 in immunology and molecular biology respectively by ScholarsGPS, based on lifetime achievements calculated by  discipline related h-factors. University Health Network UHN Research Princess Margaret Cancer Centre scholargps.com/scholars